Drug Type Small molecule drug |
Synonyms Ilorasertib (USAN), A-968660, A-968660.0 + [3] |
Action antagonists, inhibitors |
Mechanism PDGFR antagonists(Platelet-derived growth factor receptor antagonists), SRC inhibitors(Tyrosine-protein kinase SRC inhibitors), AURK inhibitors(Serine/threonine-protein kinase Aurora inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC25H21FN6O2S |
InChIKeyWPHKIQPVPYJNAX-UHFFFAOYSA-N |
CAS Registry1227939-82-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 05 Aug 2016 | |
Acute Lymphoblastic Leukemia | Phase 1 | United States | 01 Apr 2010 | |
Acute Myeloid Leukemia | Phase 1 | United States | 01 Apr 2010 | |
Chronic Lymphocytic Leukemia | Phase 1 | United States | 01 Apr 2010 | |
Myelodysplastic Syndromes | Phase 1 | United States | 01 Apr 2010 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 1 | United States | 01 Apr 2010 | |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Mar 2010 | |
Hematologic Neoplasms | Phase 1 | United States | - |
Phase 1 | 58 | efgetsffda(ezsogjmltx) = fatigue (48%), anorexia (34%), and hypertension (34%) svdgtjmxxz (xowktccgth ) View more | Positive | 01 Apr 2018 | |||
Phase 1 | 52 | aqrgcxwrqc(vwtoywfrgf) = hypertension (28.8 %), hypokalemia (15.4 %), anemia (13.5 %), and hypophosphatemia (11.5 %) awlijvtozb (zlnzktgnxl ) View more | Positive | 01 Aug 2015 |